论文部分内容阅读
目的探讨恶性淋巴瘤患者血浆中丝切蛋白(cofilin)含量变化及其临床意义。方法 50例经术后病理检查证实为恶性淋巴瘤患者作为恶性淋巴瘤组,选取同期进行健康体检的健康者30例作为对照组,采用酶联免疫吸附法测定两组血浆cofilin的含量。结果恶性淋巴瘤组患者血浆cofilin含量为(0.792±0.436)mg/L,对照组为(0.231±0.143)mg/L,恶性淋巴瘤组患者血浆cofilin含量高于对照组(P<0.05)。恶性淋巴瘤患者血浆cofilin含量与性别、年龄及病理类型无关(P>0.05),与患者的临床分期有关(P<0.05)。结论 cofilin在恶性淋巴瘤患者中含量较高,且和临床分期有关,检测血浆cofilin含量有助于评估恶性淋巴瘤的临床分期。
Objective To investigate the plasma cofilin content in patients with malignant lymphoma and its clinical significance. Methods Fifty patients with malignant lymphoma confirmed by postoperative pathology were selected as the malignant lymphoma group. Thirty healthy controls were selected as control group. Plasma cofilin levels were measured by enzyme-linked immunosorbent assay. Results The plasma levels of cofilin were (0.792 ± 0.436) mg / L in patients with malignant lymphoma and (0.231 ± 0.143) mg / L in patients with malignant lymphoma. The levels of plasma cofilin in patients with malignant lymphoma were significantly higher than those in controls (P <0.05). The plasma level of cofilin in patients with malignant lymphoma had no correlation with gender, age and pathological type (P> 0.05), and was related to the clinical stage (P <0.05). Conclusions cofilin is highly expressed in patients with malignant lymphoma and is related to clinical stage. The detection of plasma cofilin content is helpful to evaluate the clinical stage of malignant lymphoma.